OLEMA PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Increase (Decrease) in Accounts Payable of -$7.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.91M, a 356.39% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$5.68M.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $5.77M, a 128.81% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $2.39M.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2025 was $4.60M, a 83.19% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2024 was $2.51M, a 8.00% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2023 was $2.32M, a 562.11% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2022 was $351.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$7.59M 10-Q · filed 2026-08-10 | -$1.81M derived: sum of 3 quarters · filed 2026-08-10 | $578.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$5.68M 10-Q · filed 2026-05-12 | $92.00K derived: sum of 2 quarters · filed 2026-05-12 | $2.48M derived: sum of 3 quarters · filed 2026-05-12 | $3.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.16M derived: sum of 2 quarters · filed 2026-03-16 | $8.91M derived: sum of 3 quarters · filed 2026-08-10 | $4.60M 10-K · filed 2026-03-16 |
| 2025-09-30 | $2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.13M derived: sum of 2 quarters · filed 2026-08-10 | -$1.18M 10-Q · filed 2025-11-10 | $1.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $743.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$3.57M 10-Q · filed 2026-08-10 | -$1.04M derived: sum of 3 quarters · filed 2026-08-10 | -$2.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$4.31M 10-Q · filed 2026-05-12 | -$1.79M derived: sum of 2 quarters · filed 2026-05-12 | -$3.46M derived: sum of 3 quarters · filed 2026-05-12 | -$6.76M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $854.00K derived: sum of 2 quarters · filed 2026-03-16 | -$2.45M derived: sum of 3 quarters · filed 2026-03-16 | $2.51M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$4.97M derived: sum of 2 quarters · filed 2025-11-10 | -$13.00K 10-Q · filed 2025-11-10 | $478.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.66M 10-Q · filed 2025-08-11 | $2.15M derived: sum of 3 quarters · filed 2025-08-11 | $2.73M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $4.96M 10-Q · filed 2025-05-13 | $5.45M derived: sum of 2 quarters · filed 2025-05-13 | $6.03M derived: sum of 3 quarters · filed 2025-05-13 | $6.97M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.07M derived: sum of 2 quarters · filed 2025-03-18 | $2.02M derived: sum of 3 quarters · filed 2025-03-18 | $2.32M 10-K · filed 2025-03-18 |
| 2023-09-30 | $582.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.53M derived: sum of 2 quarters · filed 2024-11-12 | $1.83M 10-Q · filed 2024-11-12 | $2.19M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $944.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.25M 10-Q · filed 2024-08-06 | $1.61M derived: sum of 3 quarters · filed 2024-08-06 | $1.50M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $307.00K 10-Q · filed 2024-05-08 | $667.00K derived: sum of 2 quarters · filed 2024-05-08 | $561.00K derived: sum of 3 quarters · filed 2024-05-08 | $413.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $360.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $254.00K derived: sum of 2 quarters · filed 2024-03-11 | $106.00K derived: sum of 3 quarters · filed 2024-03-11 | $351.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | -$106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$254.00K derived: sum of 2 quarters · filed 2023-11-07 | -$9.00K 10-Q · filed 2023-11-07 | -$165.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $97.00K 10-Q · filed 2023-08-08 | -$59.00K derived: sum of 3 quarters · filed 2023-08-08 | -$264.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $245.00K 10-Q · filed 2023-05-09 | $89.00K derived: sum of 2 quarters · filed 2023-05-09 | -$116.00K derived: sum of 3 quarters · filed 2023-05-09 | -$111.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$361.00K derived: sum of 2 quarters · filed 2023-03-09 | -$356.00K derived: sum of 3 quarters · filed 2023-03-09 | -$683.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$200.00K derived: sum of 2 quarters · filed 2022-11-08 | -$527.00K 10-Q · filed 2022-11-08 | $92.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$322.00K 10-Q · filed 2022-08-09 | $297.00K derived: sum of 3 quarters · filed 2022-08-09 | -$631.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$327.00K 10-Q · filed 2022-05-09 | $292.00K derived: sum of 2 quarters · filed 2022-05-09 | -$636.00K derived: sum of 3 quarters · filed 2022-05-09 | $178.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $619.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$309.00K derived: sum of 2 quarters · filed 2022-02-28 | $505.00K derived: sum of 3 quarters · filed 2022-02-28 | -$220.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | -$928.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$114.00K derived: sum of 2 quarters · filed 2021-11-10 | -$839.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $814.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $89.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$725.00K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $810.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |